BeOne Medicines AG develops cancer medicines and conducts research and clinical development in oncology, focusing on targeted therapies for hematologic malignancies and solid tumors. The company advances a pipeline of investigational therapies, runs global clinical trials and collaborates on development, manufacturing and patient access.
AI-generated
Offering
Products & services
Industry:Holding Companies
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Cancer medicines, including BRUKINSA (zanubrutinib), TEVIMBRA (tislelizumab-jsgr) and BEQALZI (sonrotoclax).
Clinical trials
Clinical trials in haematology, lung cancer, stomach cancer, breast cancer and other indications; opportunities to participate and obtain information for patients and healthcare professionals.
Research and development
Research and development for oncology therapies with a focus on haematology and solid tumours, as well as approaches such as CDACs and antibody drug conjugates.
Patient Support Program
Personalised support for prescribed patients, including insurance and co-pay assistance, education and help with financial, advisory and transportation needs.
Expanded Access Program
Access to investigational products for patients with no other treatment options and not participating in a clinical trial, in compliance with local regulations.
Knowledge
No knowledge articles yet
Once BeOne Medicines AG has claimed this profile, we'll publish editorial articles and case studies here together.